Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024.

“Personalis is excited to present data showing our ultra-sensitive MRD test, NeXT Personal, has the potential to find recurrent cancer earlier and monitor response in late-stage cancer patients receiving immunotherapy,” said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Personalis will be sharing progress with collaborative research findings as well as the latest clinical results related to NeXT Personal. Highlights include:

• Mini-symposium (Liquid Biopsy): Ultra-sensitive ctDNA detection predicts response to immune checkpoint inhibition in advanced melanoma patients
  • Speaker: Dr. Christoffer Gebhardt
  • Date & Time: Tuesday, April 9, 2:55 PM - 3:10 PM
  • Location: Room 6 CF - Upper Level - Convention Center

ctDNA dynamics detected with NeXT Personal were predictive of patient response and outcomes in melanoma patients receiving immunotherapy; over a third of ctDNA detections were in the ultra-sensitive range (<100 PPM) in advanced melanoma patients.

• Abstract Title: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune-checkpoint blockade
  • Session Date & Time: Sunday, Apr 7, 2024 1:30 PM - 5:00 PM
  • Location: Poster Section 40, Number 17
  • Abstract Number: 976

Changes in ctDNA levels detected with NeXT Personal predicted therapy response and overall survival in late-stage hepatocellular carcinoma patients treated with a personalized cancer vaccine.

• Abstract Title: Analytic validation of an ultra-sensitive tumor-informed circulating tumor DNA assay based on whole genome sequencing
  • Session Date & Time: Tuesday, Apr 9, 2024 9:00 AM - 12:30 PM
  • Location: Poster Section 40, Number 21
  • Abstract Number: 5034

Analytical validation of NeXT Personal demonstrated ultra-sensitivity down to 1 PPM of ctDNA and high specificity, reinforcing the potential to detect recurrent cancer earlier.